11/21
07:05 am
qure
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
Low
Report
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
11/6
02:10 pm
qure
uniQure (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
uniQure (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
11/6
01:10 pm
qure
uniQure (NASDAQ: QURE) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $10.00 to $9.00. They now have a "neutral" rating on the stock.
Low
Report
uniQure (NASDAQ: QURE) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $10.00 to $9.00. They now have a "neutral" rating on the stock.
11/6
12:23 pm
qure
uniQure (NASDAQ: QURE) had its price target lowered by analysts at Royal Bank of Canada from $16.00 to $14.00. They now have an "outperform" rating on the stock.
Low
Report
uniQure (NASDAQ: QURE) had its price target lowered by analysts at Royal Bank of Canada from $16.00 to $14.00. They now have an "outperform" rating on the stock.
11/6
10:18 am
qure
uniQure (NASDAQ: QURE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
High
Report
uniQure (NASDAQ: QURE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
11/5
10:05 am
qure
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/5
07:05 am
qure
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
High
Report
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
10/17
02:01 am
qure
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
10/15
07:05 am
qure
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
Low
Report
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
10/10
09:36 am
qure
uniQure (NASDAQ: QURE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $20.00 price target on the stock.
Medium
Report
uniQure (NASDAQ: QURE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $20.00 price target on the stock.
9/23
07:05 am
qure
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
Medium
Report
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
9/20
01:29 pm
qure
uniQure (NASDAQ: QURE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
Low
Report
uniQure (NASDAQ: QURE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.